On Jan. 5, 2023, BioNTech announced that the Company had signed a Memorandum of Understanding with the Government of the United Kingdom to benefit patients by accelerating clinical trials for personalized mRNA immunotherapies with the aim to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either in clinical trials or as authorized treatments.